Structure Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
GPCR$21.73+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(IN THOUSANDS)
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| · · THREE MONTHS ENDED · | |||||||
| · · March 31, · | |||||||
| · 2024 · 2023 | |||||||
| Cash flows from operating activities | | | | | | | |
| Net loss | | $(26,036) | | $(17,975) | | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | |
| Share-based compensation expense | | 2,744 | | 2,533 | | ||
| Depreciation expense | | 222 | | 70 | | ||
| Non-cash lease expense | | 438 | | 84 | | ||
| Accretion of net investment discounts | | (3,277) | | (346) | | ||
| Changes in operating assets and liabilities: | | | | | | | |
| Prepaid expenses and other current assets | | (6,626) | | (3,045) | | ||
| Other non-current assets | | (2) | | (59) | | ||
| Accounts payable | | 1,819 | | (923) | | ||
| Accrued expenses and other current liabilities | | (3,034) | | (555) | | ||
| Operating lease liabilities | | (328) | | (92) | | ||
| Net cash used in operating activities | | (34,080) | | (20,308) | | ||
| Cash flows from investing activities | | | | ||||
| Purchases of short-term investments | | (31,920) | | (190,096) | | ||
| Maturities of short-term investments | | 33,500 | | 141,080 | | ||
| Purchases of property and equipment | | (162) | | — | | ||
| Net cash provided by (used in) investing activities | | 1,418 | | (49,016) | | ||
| Cash flows from financing activities | | | | ||||
| Proceeds from issuance of common stock in initial public offering, net of underwriting discount and commissions | | — | | 172,296 | | ||
| Payments of offering costs | | | (53) | | | (2,601) | |
| Proceeds from exercise of share options | | 755 | | 31 | | ||
| Net cash provided by financing activities | | 702 | | 169,726 | | ||
| Net change in cash and cash equivalents | | (31,960) | | 100,402 | | ||
| Cash and cash equivalents | | | | ||||
| Beginning of the period | | 129,792 | | 26,091 | | ||
| End of the period | | $97,832 | | $126,493 | | ||
| Supplemental disclosures of noncash investing and financing activities | | | | ||||
| Conversion of redeemable convertible preferred shares into ordinary shares upon initial public offering | | $— | | $199,975 | | ||
| Offering costs included in accounts payable and accrued expenses and other current liabilities | | $— | | $416 | | ||
| | | | | | | | |
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.